Cargando…
Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer
BACKGROUND: There are robust data supporting the contribution of oxaliplatin (L-OHP) regarding clinical outcomes for colorectal cancer (CRC) in an adjuvant setting in European and US trials; however, there is no Japanese clinical evidence although L-OHP has been approved since 2009. We examined the...
Autores principales: | Osumi, Hiroki, Shinozaki, Eiji, Suenaga, Mitsukuni, Wakatsuki, Takeru, Nakayama, Izuma, Matsushima, Tomohiro, Ogura, Mariko, Ichimura, Takashi, Takahari, Daisuke, Chin, Keisho, Nagasaki, Toshiya, Konishi, Tsuyoshi, Akiyoshi, Takashi, Fujimoto, Yoshiya, Nagayama, Satoshi, Fukunaga, Yosuke, Ueno, Masashi, Yamaguchi, Kensei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451009/ https://www.ncbi.nlm.nih.gov/pubmed/28562679 http://dx.doi.org/10.1371/journal.pone.0176745 |
Ejemplares similares
-
Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel
por: Fukuda, Naoki, et al.
Publicado: (2018) -
Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer
por: Nakayama, Izuma, et al.
Publicado: (2018) -
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
por: Nakayama, Izuma, et al.
Publicado: (2017) -
Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018) -
Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake
por: Osumi, Hiroki, et al.
Publicado: (2018)